Allergy

Autoimmune Diseases

Biosimilars

COVID-19

Cannabidiol (CBD)

Cardiology

Compounding

Continuous Glucose Monitoring

Dermatology

Diabetes

Digestive Health

Endocrinology

Eye Health

Generics

Headache and Migraine

Immunization

Infectious Disease

Influenza

Medical Devices

Mental and Behavioral Health

Neurology

Obesity Management

Oncology

Nonopioid Pain Management

Pain Management

Pediatrics

Public Health

Rare Diseases

Respiratory

Rheumatology

Shingles

Substance Use Disorder

Technology and Data

Veterinary Pharmacy 

Women's Health

News

FDA Updates

Law and Advocacy

Technology Trends

Viewpoints

All News

Media

Around the Practice

In-Depth Insights

K-Casts

Script-Ed

Expert Interviews

Podcasts

Conferences

Conference Coverage

Conference Listing

Resources

Disease Awareness 

White Board Video

American Pharmacists Month

CME/CE

Partners

Publications

Drug Topics Journal

Total Pharmacy Journal

Events

Virtual Events

Total Pharmacy Solutions Summit

Business

Business Strategies

Patient Services

Pharmacy Inventory

Law and Regulations

All Business News

Practice Type

Independent Pharmacy

Chain Pharmacy

Specialty Pharmacy

Health System Pharmacy

Pharmacy Technicians

Subscribe

Articles

Two posted presented at the American Heart Association’s 2024 Scientific Sessions explored empagliflozin among patients with type 2 diabetes and cardiovascular risk.

Evaluating Empagliflozin’s Impact on Cardiovascular Outcomes in Patients with T2D | AHA 2024

A collection of hospitals in Rochester, New York, have teamed up to create better access to prescription drugs and combat the city’s pharmacy desert issue.

Rochester Pharmacy Access Coalition Uniting to Fill Gaps from Pharmacy Closures

Slideshows

Three research posters presented at the American Heart Association’s 2024 Scientific Sessions looked into the use of SGLT-2 inhibitors in patients with type 2 diabetes and cardiovascular complications. 

Assessing SGLT-2 Inhibitors in Patients with T2D, Cardiovascular Complications | AHA 2024

Patients with type 2 diabetes who had eating problems and higher levels of diabetes distress had worse time-in-range.


Eating Problems, Diabetes Distress Associated with Worse Time-in-Range | AHA 2024

About

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Drug Topics

Facebook

LinkedIn

Spotlight

NCPA Annual Convention

1rem

Drug Topics Journals

Total Pharmacy October 2024

Total Pharmacy August 2024

Total Pharmacy June 2024

Total Pharmacy April 2024

Total Pharmacy February 2024

Total Pharmacy December 2023

Total Pharmacy September 2023

Total Pharmacy June 2023

Total Pharmacy March 2023

Total Pharmacy January 2023 